The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Iakovleva, Irina ^a   Begum, Afshan ^a   Pokrzywa, Malgorzata ^b   Walfridsson, Malin ^a   Sauer Eriksson, A Elisabeth ^a   Olofsson, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b Department of Chemistry Umeå University ^*  (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

LUTEOLIN; LUTEOLIN 7 GLUCOSIDE; PREALBUMIN; DROSOPHILA PROTEIN; FLAVONE DERIVATIVE; GLUCOSIDE; LUTEOLIN-7-O-GLUCOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; CYTOTOXICITY; DROSOPHILA MELANOGASTER; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; FAMILIAL AMYLOID POLYNEUROPATHY; IN VIVO STUDY; NEUROBLASTOMA CELL; NONHUMAN; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STABILITY; AMYLOIDOSIS; ANIMAL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

DROSOPHILA MELANOGASTER;

AMYLOIDOSIS; ANIMALS; CELL LINE, TUMOR; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; FLAVONES; GLUCOSIDES; HUMANS; LUTEOLIN; PREALBUMIN; PROTEIN STABILITY;

EID: 84935005411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128222     Document Type: Article

References (52)

1. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Current pharmaceutical design. 2008;14(30):3219-30. Epub 2008/12/17. PMID: 19075702.
2. Kalkunte SS, Neubeck S, Norris WE, Cheng SB, Kostadinov S, Vu Hoang D, et al. Transthyretin isdysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model. The American journal of pathology. 2013;183(5):1425-36. Epub 2013/09/17. doi: 10.1016/j. ajpath.2013.07.022 PMID: 24035612; PubMed Central PMCID: PMC3814653.
3. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis. 2003;10(3):160-84. Epub 2003/12/03. doi: 10. 3109/13506120308998998 PMID: 14640030.
4. McCutchen SL, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry. 1993;32(45):12119-27. Epub 1993/11/16. PMID: 8218290.
5. Colon W, Lai Z, McCutchen SL, Miroy GJ, Strang C, Kelly JW. FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation. Ciba Foundation symposium. 1996;199:228-38; discussion 39-42. Epub 1996/01/01. PMID: 8915613.
6. Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 1996;35(20):6470-82. Epub 1996/05/21. doi: 10.1021/bi952501g PMID: 8639594.
7. Foss TR, Kelker MS, Wiseman RL, Wilson IA, Kelly JW. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. Journal of molecular biology. 2005;347(4):841-54. Epub 2005/03/17. doi: 10.1016/j.jmb.2005.01.050 PMID: 15769474.
8. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. Journal of medicinal chemistry. 2004;47(2):355-74. Epub 2004/01/09. doi: 10.1021/jm030347n PMID: 14711308.
9. Sharma P, Perri RE, Sirven JE, Zeldenrust SR, Brandhagen DJ, Rosen CB, et al. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver transplantation: official publication of the American Association forthe Study of Liver Diseases and the International LiverTransplantation Society. 2003;9(12):1273-80. Epub 2003/11/20. doi: 10.1016/j.lts.2003.09.016 PMID: 14625827.
10. Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis. 2013;20(3):142-50. Epub 2013/05/30. doi: 10.3109/13506129.2013.797890 PMID: 23713495.
11. Okamoto S, Zhao Y, Lindqvist P, Backman C, Ericzon BG, Wijayatunga P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis. 2011;18(4):200-5. Epub 2011/11/15. doi: 10.3109/13506129.2011. 615872 PMID: 22080763.
12. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. The New England journal of medicine. 2013;369(9):819-29. Epub 2013/08/30. doi: 10.1056/NEJMoa1208760 PMID: 23984729.
13. Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(24):9992-7. Epub 2013/05/30. doi: 10.1073/pnas.1300761110 PMID: 23716704; PubMed Central PMCID: PMC3683741.
14. Grimster NP, Connelly S, Baranczak A, Dong J, Krasnova LB, Sharpless KB, et al. Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate. Journal of the American Chemical Society. 2013;135(15):5656-68. Epub 2013/01/29. doi: 10.1021/ja311729d PMID: 23350654; PubMed Central PMCID: PMC3630275.
15. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(24):9629-34. Epub 2012/05/31. doi: 10.1073/pnas.1121005109 PMID: 22645360; PubMed Central PMCID: PMC3386102.
16. Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Current opinion in structural biology. 2010;20(1):54-62. Epub 2010/02/06. doi: 10.1016/j.sbi.2009.12.009 PMID: 20133122; PubMed Central PMCID: PMC2830738.
17. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Laboratory investigation; a journal of technical methods and pathology. 2004;84(5):545-52. Epub 2004/02/18. doi: 10.1038/labinvest.3700059 PMID: 14968122.
18. Green NS, Palaninathan SK, Sacchettini JC, Kelly JW. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. Journal of the American Chemical Society. 2003;125(44):13404-14. Epub 2003/10/30. doi: 10.1021/ja030294z PMID: 14583036.
19. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposingdiflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA: the journal of the American Medical Association. 2013;310(24):2658-67. Epub 2013/12/26. doi: 10.1001/jama.2013.283815 PMID: 24368466.
20. Coelho T, Maia LF, Da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of neurology. 2013;260(11):2802-14. Epub 2013/08/27. doi: 10.1007/s00415-013-7051-7 PMID: 23974642; PubMed Central PMCID: PMC3825212.
21. Coelho T, Maia LF, Martins Da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-92. Epub 2012/07/31. doi: 10.1212/WNL.0b013e3182661eb1 PMID: 22843282.
22. Turner RA, Shackleford RW, Whipple JP. Comparison of diflunisal and aspirin in long-term treatment of patients with rheumatoid arthritis. Clinical therapeutics. 1986;9 Suppl C: 37-46. Epub 1986/01/01. PMID: 3548985.
23. Trivella DB, Sairre MI, Foguel D, Lima LM, Polikarpov I. The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition. Journal of structural biology. 2011;173(2):323-32. Epub 2010/10/13. doi: 10.1016/j.jsb.2010.10.003 PMID: 20937391.
24. Trivella DB, Dos Reis CV, Lima LM, Foguel D, Polikarpov I. Flavonoid interactions with human transthyretin: combined structural and thermodynamic analysis. Journal of structural biology. 2012;180(1):143-53. Epub 2012/07/31. doi: 10.1016/j.jsb.2012.07.008 PMID: 22842046.
25. Bastianetto S, Krantic S, Chabot JG, Quirion R. Possible involvement of programmed cell death pathways in the neuroprotective action of polyphenols. Current Alzheimer research. 2011;8(5):445-51. Epub 2011/05/25. PMID: 21605053.
26. Dajas F, Andres AC, Florencia A, Carolina E, Felicia RM. Neuroprotective actions of flavones and flavonols: mechanisms and relationship to flavonoid structural features. Central nervous system agents in medicinal chemistry. 2013;13(1):30-5. Epub 2012/10/25. PMID: 23092407.
27. Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clinical therapeutics. 2013;35(5):592-602. Epub 2013/05/22. doi: 10.1016/j.clinthera.2013.04. 006 PMID: 23688534.
28. Reixach N, Adamski-Werner SL, Kelly JW, Koziol J, Buxbaum JN. Cell based screening of inhibitors of transthyretin aggregation. Biochemical and biophysical research communications. 2006;348(3):889-97. Epub 2006/08/15. doi: 10.1016/j.bbrc.2006.07.109 PMID: 16904635.
29. Lindhagen-Persson M, Vestling M, Reixach N, Olofsson A. Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis. 2008;15(4):240-5. Epub 2008/12/10. doi: 10.1080/13506120802524916 PMID: 19065295.
30. Pokrzywa M, Dacklin I, Hultmark D, Lundgren E. Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. The European journal of neuroscience. 2007;26(4):913-24. Epub 2007/08/24. doi: 10.1111/j.1460-9568.2007.05728.x PMID: 17714186.
31. Hornberg A, Eneqvist T, Olofsson A, Lundgren E, Sauer-Eriksson AE. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. Journal of molecular biology. 2000;302(3):649-69. Epub 2000/09/15. doi: 10.1006/jmbi.2000.4078 PMID: 10986125.
32. Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73-85. Epub 2005/04/12. doi: 10.1016/j.cell.2005.01.018 PMID: 15820680.
33. Hammarstrom P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293(5539):2459-62. Epub 2001/09/29. doi: 10.1126/science.1062245 PMID: 11577236.
34. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(26):15051-6. Epub 1996/12/24. PMID: 8986762; PubMed Central PMCID: PMC26354.
35. Cardoso I, Almeida MR, Ferreira N, Arsequell G, Valencia G, Saraiva MJ. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. The Biochemical journal. 2007;408(1):131-8. Epub 2007/08/09. doi: 10.1042/BJ20070689 PMID: 17683281; PubMed Central PMCID: PMC2049069.
36. Gavrin LK, Denny RA, Saiah E. Small molecules that target protein misfolding. Journal of medicinal chemistry. 2012;55(24):10823-43. Epub 2012/10/19. doi: 10.1021/jm301182j PMID: 23075044.
37. Johnson SM, Petrassi HM, Palaninathan SK, Mohamedmohaideen NN, Purkey HE, Nichols C, et al. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. Journal of medicinal chemistry. 2005;48(5):1576-87. Epub 2005/03/04. doi: 10.1021/jm049274d PMID: 15743199.
38. Morais-De-Sa E, Pereira PJ, Saraiva MJ, Damas AM. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. The Journal of biological chemistry. 2004;279(51):53483-90. Epub 2004/10/08. doi: 10.1074/jbc. M408053200 PMID: 15469931.
39. Sant'anna RO, Braga CA, Polikarpov I, Ventura S, Lima LM, Foguel D. Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis. International journal of molecular sciences. 2013;14(3):5284-311. Epub 2013/03/08. doi: 10.3390/ijms14035284 PMID: 23466880; PubMed Central PMCID: PMC3634512.
40. Yokoyama T, Kosaka Y, Mizuguchi M. Crystal structures of human transthyretin complexed with glabridin. Journal of medicinal chemistry. 2014;57(3):1090-6. Epub 2014/01/16. doi: 10.1021/jm401832j PMID: 24422526.
41. Pokrzywa M, Dacklin I, Vestling M, Hultmark D, Lundgren E, Cantera R. Uptake of aggregating transthyretin by fat body in a Drosophila model forTTR-associated amyloidosis. PloS one. 2010;5(12):e14343. Epub 2010/12/24. doi: 10.1371/journal.pone.0014343 PMID: 21179560; PubMed Central PMCID: PMC3002944.
42. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(9):2817-22. Epub 2004/02/26. doi: 10.1073/pnas.0400062101 PMID: 14981241; PubMed Central PMCID: PMC365703.
43. Lu X, Sun D, Chen Z, Ye J, Wang R, Li L, et al. Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes. Die Pharmazie. 2011;66(8):600-5. Epub 2011/09/10. PMID: 21901983.
44. O'Brien J, Wilson I, Orton T, Pognan F. Investigation of the AlamarBlue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. European journal of biochemistry/FEBS. 2000;267(17):5421-6. Epub 2000/08/22. PMID: 10951200.
45. Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. Journal of medicinal chemistry. 2009;52(4):1115-25. Epub 2009/02/05. doi: 10.1021/jm801347s PMID: 19191553; PubMed Central PMCID: PMCPmc2698027.
46. Kabsch W. Xds. Acta crystallographica Section D, Biological crystallography. 2010;66(Pt 2):125-32. Epub 2010/02/04. doi: 10.1107/S0907444909047337 PMID: 20124692; PubMed Central PMCID: PMC2815665.
47. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al. Overview of the CCP4 suite and current developments. Acta crystallographica Section D, Biological crystallography. 2011;67(Pt 4):235-42. Epub 2011/04/05. doi: 10.1107/s0907444910045749 PMID: 21460441; PubMed Central PMCID: PMCPmc3069738.
48. Vagin A, Teplyakov A. MOLREP: an automated program for molecular replacement. Journal of Applied Crystallography. 1997;30(6):1022-5.
49. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5forthe refinement of macromolecular crystal structures. Acta crystallographica Section D, Biological crystallography. 2011;67(Pt4):355-67. Epub 2011/04/05. doi: 10.1107/S0907444911001314 PMID: 21460454; PubMed Central PMCID: PMC3069751.
50. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta crystallographica Section D, Biological crystallography. 2004;60(Pt 12 Pt 1):2126-32. Epub 2004/12/02. doi: 10.1107/S0907444904019158 PMID: 15572765.
51. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica Section D, Biological crystallography. 2010;66(Pt2):213-21. Epub 2010/02/04. doi: 10.1107/S0907444909052925 PMID: 20124702; PubMed Central PMCID: PMC2815670.
52. McNicholas S, Potterton E, Wilson KS, Noble ME. Presenting your structures: the CCP4mg moleculargraphics software. Acta crystallographica Section D, Biological crystallography. 2011;67(Pt 4):386-94. Epub 2011/04/05. doi: 10.1107/s0907444911007281 PMID: 21460457; PubMed Central PMCID: PMCPmc3069754.